Product Images Rosuvastatin Calcium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 5 images provide visual information about the product associated with Rosuvastatin Calcium NDC 68071-3722 by Nucare Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
pdp - 68071 3722 9
This is a description of a medication called Rosuvastatin 10mg, distributed by NuCare Pharmaceuticals, Inc. It comes in a pack of 90 film-coated tablets. Each tablet contains Rosuvastatin and Calcium USP equivalent to 10mg of Rosuvastatin. The LOT number is 00000 with NDC number 68071-3722-09. The manufacturer's NDC is 65862-294-90 and the expiration date is 00-00. There is information regarding contacting a doctor for medical advice about potential side effects and reporting such side effects to the FDA. The medication needs to be kept out of reach of children and stored at a controlled temperature of 68-77°F.*
Figure 1. Time to First Occurrence of Major Cardiovascular Events in JUPITER - rosuvastatin fig1
This text appears to be providing statistical evidence regarding a clinical trial. It includes hazard ratios (HR) and confidence intervals (CI) for different treatment groups, as well as the number at risk in each group over multiple years. The statistics suggest a significant difference between the treatment group (Rosuvastatin) and the placebo group (RSV) in terms of the outcome being measured.*
Figure 2. Major CV Events by Treatment Group in JUPITER - rosuvastatin fig2
This text appears to be a statistical analysis of clinical trial results comparing the effects of Roswa20mg and Placebo20mg on various cardiovascular endpoints. The data includes the number of events for each endpoint, hazard ratios with confidence intervals, and corresponding p-values for statistical significance. The primary endpoint (MCE) and other outcomes such as cardiovascular death, stroke, and MI are compared between the two treatment groups. The results suggest that Roswa20mg may be associated with a lower risk of adverse cardiovascular events compared to Placebo20mg.*
Figure 3. - rosuvastatin fig3
This text provides information on the percent change from baseline in LDL-C levels for different doses of rosuvastatin, atorvastatin, simvastatin, and pravastatin. The doses mentioned for each statin are 10, 20, and 40 mg except for atorvastatin, which also includes a dose of 80 mg. This data can be used to compare and evaluate the efficacy of these statins in lowering LDL cholesterol levels.*
Chemical Structure - rosuvastatin str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
